Similar names for similar biologics

BioDrugs

Volumn 28, Issue 5, 2014, Pages 439-444

  Casadevall, Nicole ^a   Felix, Thomas ^b   Strober, Bruce E ^c,d   Warnock, David G ^e  

^a HÔPITAL SAINT ANTOINE   (France)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d PROBITY MEDICAL RESEARCH   (Canada)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

DRUG APPROVAL; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; NOMENCLATURE; ORGANIZATION AND MANAGEMENT; STANDARDS; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG SUBSTITUTION; HUMANS; PHARMACOVIGILANCE; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930720482     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0099-9     Document Type: Review

References (39)

1. Biologics Price Competition and Innovation Act of 2009. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed 18 February 2014.
2. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-8.
3. European public assessment reports: biosimilars. European Medicines Agency, London, UK. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar-search.jsp&murl=menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 18 February 2014.
4. IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health, London. 2011. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars-Whitepaper.pdf. Accessed 18 February 2014.
5. World Health Organization. Executive summary: 55th consultation on international nonproprietary names for pharmaceutical substances. Geneva, Switzerland. 2013. http://www.who.int/medicines/services/inn/55th-Executive-Summary.pdf. Accessed 18 February 2014.
6. Dolinar R. It's all about the name: what is the imperative of adopting unique names for biologic and biosimilar therapeutics? Food Drug Policy Forum. 2012;2(22):1-19.
7. Miller S. Is it necessary to depart from international naming conventions for biosimilars in the US to ensure the safety of biologic and biosimilar therapeutics? A response to 'It's all about the name: what is the imperative of adopting unique names for biologic and biosimilar therapeutics?'. Food Drug Policy Forum. 2013;3(1):1-24.
8. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, et al. Pharmacovigilance and biosimilars: considerations, needs, and challenges. Expert Opin Biol Ther. 2013;13(7):1039-47.
9. Australian Government Department of Health Therapeutic Goods Administration. Evaluation of biosimilars: naming conventions for biosimilars. 2013. http://www.tga.gov.au/industry/pm-argpm-biosimilars-10.htm. Accessed 18 February 2014.
10. Bogaert P, Lietzan E, Sim L. Biosimilar regulation: important considerations and global developments. In: Cross-border life sciences handbook. Practical Law Company. 2011. http://www.cov.com/files/Publication/675a60c0-58e3-41fe-82a7-48120814f04a/Presentation/PublicationAttachment/3966b7f6-690a-4380-bd70-5501df1c5e74/Biosimilar%20regulation%20-%20important%20considerations%20and%20global%20developments%20-%202011.pdf. Accessed 18 February 2014.
11. Felix T, Johansson TT, Colliatie JA, Goldberg MR, Fox AR. Biologic product identification and US pharmacovigilance in the biosimilars era. Nat Biotechnol. 2014;32(2):128-30.
12. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville: US Food and Drug Administration; 2012.
13. US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Rockville: US Food and Drug Administration; 2012.
14. US Food and Drug Administration. Guidance for industry: biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Rockville: US Food and Drug Administration; 2012.
15. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2006 (report no. EMEA/CHMP/BMWP/42832/2005).
16. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London: European Medicines Agency; 2006 (report no. EMEA/CHMP/BWP/49348/2005).
17. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: World Health Organization; 2009.
18. European Medicines Agency. Guideline on similar biological medicinal products. London: European Medicines Agency; 2005 (report no. CHMP/437/04).
19. US Food and Drug Administration. FDA NDA 505(b)(1) of the FD&C Act. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM245363.pdf. Accessed 18 February 2014.
20. Sekon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011;1:1-11.
21. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): module V - risk management systems (rev 1); 2014 (report no. EMA/838713/2011 Rev 1).
22. Celltrion Healthcare Co. Ltd. Product monograph: Inflectra™ infliximab. Incheon, South Korea. 2014.
23. Celltrion Healthcare Co. Ltd. Product monograph: Remsima™ infliximab. Incheon, South Korea. 2014.
24. Olson K. Alliance for Safe Biologic Medicines - prescriber survey. Alliance for Safe Biologic Medicines. 2012. http://safebiologics.org/resources/wp-content/uploads/2012/09/ASBM-Survey-2.pdf. Accessed 18 February 2014.
25. European Commission. What you need to know about biosimilar medicinal products: a consensus information document. 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars-report-en.pdf. Accessed 18 February 2014.
26. Generics and Biosimilars Initiative. France to allow biosimilars substitution. 2014. http://www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution. Accessed 11 April 2014.
27. European Biopharmaceutical Enterprises. French biosimilar law - no generics-style substitution policy. 2014. http://www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution. Accessed 11 April 2014.
28. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12(11):1473-85.
29. Haag-Weber M, Eckardt KU, Horl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8-17.
30. Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Domergue F, Egberts TC, Leufkens HG, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Saf. 2013;36(8):617-25.
31. Directive 2010/84/EU of the European Parliament and of the Council of 15 amending, as regards pharmacovigilance, Directive 2001/83/EC on the community code relating to medicinal products for human use. Off J Eur Union. 2010;2010(348):74-99.
32. European Medicines Agency & Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): module VI - management and reporting of adverse reactions to medicinal products. London: European Medicines Agency & Heads of Medicines Agencies; 2012 (report no. EMA/873138/2011).
33. US Food and Drug Administration. Part 15 public hearing on approval pathway for biosimilar and interchangeable biological products. Silver Spring: US Food and Drug Administration; 2010.
34. Cina J, Fanikos J, Mitton P, McCrea M, Churchill W. Medication errors in a pharmacy-based bar-code-repackaging center. Am J Health Syst Pharm. 2006;63(2):165-8.
35. Booz Allen Hamilton. Evaluation of potential data sources for the FDA sentinel initiative - final report. Rockville: Booz Allen Hamilton; 2010 (report no. US Food and Drug Administration contract no. HHSF223200831321P).
36. World Health Organization. Executive summary: 56th consultation on international nonproprietary names for pharmaceutical substances. 2013. http://www.who.int/medicines/services/inn/56th-Executive-Summary.pdf. Accessed 18 February 2014.
37. US Food and Drug Administration. Proprietary name review(s): BLA 125294 - [xxx]-filgrastim. Rockville: Center for Drug Evaluation and Research; 2012 (contract no. 3169145).
38. US Food and Drug Administration. Ziv-aflibercept. 2012. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm3144htm. Accessed 18 February 2014.
39. US Food and Drug Administration. Kadcyla (ado-trastuzumab emtansine): drug safety communication - potential medication errors resulting from name confusion. 2013. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm. Accessed 18 February 2014.